# Public Comments Summary

## Themes

***Public comment adjustments are made through track changes***

* Advocacy:
	+ Increased suggestions for advocacy for elected officials
	+ Advocacy against Drug Free Workplace laws
* Equity lens *->* ***added paragraph to the background section***
* Access
	+ Buprenorphine over-the-counter buprenorphine for competent adults
	+ Emphasis on access to harm reduction services across all settings
	+ Prioritize comprehensive array of care (physical, behavioral, social needs)
	+ Emphasize reference to Hepatitis C report
* Training/Education
	+ Antiracism, Stigma and bias training and education for providers and students
	+ Overdose prevention and naloxone administration
* Accountability and flexibility of SUDPs to treat SUDs
* Prescribing of MOUD
	+ Changes for perinatal individuals (split-dosing)
* Additional resources
* Evaluation
	+ Specific indicators of interest, such as patient satisfaction
	+ Inclusion of health system improvement measures (treatment penetration, cost effectiveness, broader health outcomes for people who use drugs (QOL measures, satisfaction)
* Payment
	+ Recognition that reimbursement for peer support begins after July 2025
	+ Lower total cost of care, as may not be able to remove copays/coinsurance due to regulatory barriers from IRS
	+ Encourage building partnerships with CBOs to provide mobile vans/in-person outreach
	+ Adjustment to statement about refusing to contract with facilities/providers refusing to offer MOUD
* Changes in tables for:
	+ Primary care
	+ Behavioral health
	+ Perinatal providers
	+ Emergency department
	+ Inpatient settings
	+ Syringe service programs
* MOUD section:
	+ Additions to buprenorphine, naltrexone and naloxone